ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.
Marit A C VermuntDebbie G J RobbrechtLot A DevrieseJulie M JanssenBas ThijssenMarianne KeessenMaarten van EijkRob KesselsFerry A L M EskensJos H BeijnenNiven MehraAndries M BergmanPublished in: Cancer reports (Hoboken, N.J.) (2021)
The RP2D was established at weekly ModraDoc006/r 30-20/200-100. Observed PSA and radiological responses suggest promising clinical activity. These results have led to an ongoing randomized Phase 2b study, comparing weekly ModraDoc006/r with 3-weekly IV docetaxel in patients with mCRPC.
Keyphrases